Calla Lily Clinical Care, the London-based startup behind Callavid, a device designed to improve treatment for threatened miscarriage, has received £1 million in Invention for Innovation funding from the National Institute for Health and Care Research to support its first in-person clinical trial.
“The NIHR funding will enable us to test our technology via a feasibility study this autumn, bringing us one step closer to making this product available to help women at one of the most distressing moments of their lives,” Dr. Lara Zibners, co-founder and chair of Calla Lily Clinical Care, said in a statement.
According to a news release, Callavid enhances the delivery of micronized progesterone, a treatment recommended by the National Institute for Health and Care Excellence, or NICE, for women who have experienced at least one prior miscarriage and are experiencing bleeding in early pregnancy. The technology may also benefit women undergoing IVF.
The trial process begins this month with a usability study to ensure the device and instructions are user friendly. An NIHR-funded clinical feasibility study will follow in the second half of 2025.
